A new drug plus letrozole for advanced HR+ breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new medicine (BGB-43395) combined with letrozole against the usual CDK4/6 inhibitor plus letrozole. It is for people with advanced or metastatic HR-positive, HER2-negative breast cancer who have not yet had treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your breast cancer is HR-positive and HER2-negative and has spread to other parts of the body or is locally advanced.
- You have not had any treatment for advanced or metastatic breast cancer before.
- You are in generally good health (able to do daily activities with little or no help).
- You do not have untreated or uncontrolled brain metastases or leptomeningeal disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for advanced breast cancer that is both hormone receptor-positive (HR+) and HER2-positive. The treatment combines fulvestaciclib (a CDK4/6 inhibitor) with anti-HER2 therapy and endocrine therapy, aiming to slow or stop cancer growth. It may be an option if you have not yet had treatment for advanced disease.
This Phase 3 study tests whether GB491 used together with letrozole works better for hormone receptor–positive and HER2-negative advanced breast cancer. You may be eligible if you have not had certain prior cancer treatments and your health tests are within safe limits.
This study tests a new version of the hormone therapy drug letrozole (called Letrozole SIE) against the standard version (Femara). Both are combined with ribociclib, a drug that helps stop cancer cells from growing. The goal is to see if the new version works just as well and is safe for postmenopausal women with advanced breast cancer.
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
This study looks at how well a combination of two medicines (a CDK4/6 inhibitor and an aromatase inhibitor) works for people with a certain type of advanced breast cancer. It aims to gather real-world information to better understand treatment patterns and outcomes.
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
Hear when a new HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.